If we assume there is at least $1 billion in revenue by 2018 on a net present value basis in 2014 the SP should be around $90/share. My guess is that estimated 2018 revenues by the summer of 2014 will be more on the order of $1.5 billion and the sp on a take out basis would be $135/share. Positive results for NTM and European approval for CF will lock in this number. Anything regarding Iplex would be tacked on and just the short stature market in 2018 should be over $200 million which would add another $10/share in a 2014 takeout.
Hand, I think we need some clarification. As I type, Insmed's current market cap is 636 million. So, what are you basing Insmed's value at 1 billion? Arikace? iPlex....partnering for which indications? igfbp3? INSM-18? To me INSM has several prongs......so, it's hard to determine a prediction. I have set my personal selling price at $180......but I think I will be getting out early of true potential.
Too much eggnog. Arikace rsults not even in.I tells you dat da ntm results not be file-able youssee.
I alone in clinic not only Holiday but weekend.I do board comparator test.What insm18igfbp3 yousstupid